Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safe Step Act HR2279/S2546
Safe Step Act HR2279/S2546
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2020 · third_quarter · Q3
LHHS CDC line item
Pending regulatory rules impacting the space
Safe Step Act HR2279/S2546
Source: Senate LDA
Safe Step Act HR2279/S2546
Safe Step Act HR2279/S2546
Safe Step Act HR2279/S2546
Safe Step Act HR2279/S2546
Safe Step Act HR2279/S2546
Safe Step Act HR2279/S2546
Safe Step Act HR2279
Safe Step Act HR2279
Safe Step Act HR2279/S2546
Safe Step Act HR2279/S2546
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act. This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called speciality tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Restoring the Patient's Voice Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Patients' Access to Treatments Act of 2017
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Personal Care Products Safety Act
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Personal Care Products Safety Act
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Personal Care Products Safety Act
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Personal Care Products Safety Act
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2020 · fourth_quarter · Q4
Safe Step Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2020 · second_quarter · 2A
LHHS CDC line item
Safe Step Act HR2279/S2546
Pending regulatory rules impacting the space
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2020 · first_quarter · Q1
LHHS CDC line item
Safe Step Act HR2279/S2546
Pending regulatory rules impacting the space
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2019 · fourth_quarter · Q4
LHHS CDC line item
Safe Step Act HR2279/S2546
Pending regulatory rules impacting the space
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2019 · third_quarter · Q3
Pending regulatory rules impacting the space
LHHS CDC line item
Safe Step Act HR2279/S2546
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2019 · second_quarter · Q2
LHHS CDC line item
Safe Step Act HR2279
Pending regulatory rules impacting the space
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2019 · first_quarter · Q1
LHHS CDC line item
Safe Step Act HR2279
Pending regulatory rules impacting the space
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2018 · fourth_quarter · Q4
FY20 Appropriations for Psoriatic Disease Allocate $1 million in the Fiscal Year 2020 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.
In relation to the President's Drug Pricing Blueprint, the NPF advocated for patient priorities as they relate to potential Congressional proposals to move Medicare Part B drugs into Part D, adjust out of pocket expenses in Medicare Part D, and increase access to therapies. There was a particular focus on Congress's role in new policies around allowing step therapy protocols in Medicare Advantage plans.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2018 · third_quarter · Q3
FY19 Appropriations for Psoriatic Disease Allocate $1 million in the Fiscal Year 2019 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.
In relation to the President's Drug Pricing Blueprint, the NPF advocated for patient priorities as they relate to potential Congressional proposals to move Medicare Part B drugs into Part D, adjust out of pocket expenses in Medicare Part D, and increase access to therapies. There was a particular focus on Congress's role in new policies around allowing step therapy protocols in Medicare Advantage plans.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2018 · second_quarter · Q2
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
In relation to the President's Drug Pricing Blueprint, the NPF advocated for patient priorities as they relate to potential Congressional proposals to move Medicare Part B drugs into Part D, adjust out of pocket expenses in Medicare Part D, and increase access to therapies.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2018 · first_quarter · Q1
FY19 Appropriations for Psoriatic Disease Allocate $1 million in the Fiscal Year 2019 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2017 · fourth_quarter · Q4
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act. This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called speciality tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2017 · second_quarter · RA
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FY19 Appropriations for Psoriatic Disease Allocate $1 million in the Fiscal Year 2019 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;